BeyondSpring to Start China-US Phase III Trial of Novel Cancer Drug

BeyondSpring Pharmaceuticals, a clinical-stage cancer company, plans to start a China-US Phase III trial of its lead drug candidate, plinabulin, among patients with non-small cell lung cancer in Q1 of 2015. BeyondSpring, headquartered in New York City, is a virtual company. In plinabulin's Phase III trial, 75% of the patients will be enrolled in China and the remainder in the US. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.